Page last updated: 2024-10-27

flucytosine and Glioma

flucytosine has been researched along with Glioma in 46 studies

Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.

Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

Research Excerpts

ExcerptRelevanceReference
"5FC, 5-fluorocytosineBBB, Basso, Beattie, and BresnahanCD, cytosine deaminaseDP, diastolic blood pressureGCV, ganciclovir; hNSCs, human neural stem cellsISCG, intramedullary spinal cord gliomasMAP, mean arterial blood pressureNSCs, neural stem cellsSP, systolic blood pressureTK, thymidine kinase."3.83Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells. ( Abd-El-Barr, M; Aljuboori, Z; Anderson, JE; Chi, JH; Han, I; Haragopal, H; Kim, SU; Lee, HJ; Ropper, AE; Sidman, RL; Snyder, EY; Teng, YD; Viapiano, MS; Zeng, X, 2016)
"Since neural progenitor cells can engraft stably into brain tumors and differentiate along the neuronal and glial line, we tested the hypothesis that transplanted cytosine deaminase (CD)-expressing ST14A cells (an immortalized neural progenitor cell line) can convert locally 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and produce a regression of glioma tumors."3.72Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. ( Barresi, V; Belluardo, N; Cattaneo, E; Condorelli, DF; Mudò, G; Sipione, S, 2003)
"In this study, we investigated the feasibility of a double-suicide gene/prodrug therapy, involving direct introduction of the herpes simplex virus Type 1 thymidine kinase (TK) gene and the Escherichia coli cytosine deaminase (CD) gene, via a recombinant adenoviral vector, and ganciclovir (GCV) and/or 5-fluorocytosine (5-FC) treatment, in a rat C6 glioma model."3.70Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. ( Chang, JW; Chung, SS; Kim, E; Kim, JH; Lee, H; Lee, Y, 2000)
"Glioblastoma and anaplastic astrocytoma are two of the most aggressive and common glioma malignancies in adults."2.61Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. ( Adamson, DC; Philbrick, BD, 2019)
"High-grade gliomas are extremely difficult to treat because they are invasive and therefore not curable by surgical resection; the toxicity of current chemo- and radiation therapies limits the doses that can be used."1.39Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. ( Aboody, KS; Annala, AJ; Aramburo, S; Badie, B; Barish, ME; Blanchard, S; Brown, CE; Couture, LA; D'Apuzzo, M; Frank, RT; Garcia, E; Gutova, M; Kim, SU; Metz, MZ; Moats, RA; Najbauer, J; Portnow, J; Synold, TW; Valenzuela, VV, 2013)
" Survival benefit is dose dependent for both vector and 5-FC, and as few as 4 cycles of 5-FC dosing after Toca 511 therapy provides significant survival advantage."1.38Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. ( Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT, 2012)
"Immunohistochemistry of rat brain tumors inoculated with MSC-EGFP showed intratumoral distribution of MSC-EGFP."1.38Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. ( Date, I; Hamada, H; Ichikawa, T; Inoue, S; Kambara, H; Kosaka, H; Kurozumi, K; Maruo, T; Nakamura, K, 2012)
"Medulloblastomas are highly malignant neuroectodermal cerebellar tumors of children."1.34Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma. ( Bang, JH; Fujii, M; Ito, M; Ito, S; Kim, SU; Natsume, A; Park, IH; Shimato, S; Takeuchi, H; Wakabayashi, T; Yoshida, J, 2007)
"The infection of RG2 brain tumors with RCR-CD and their subsequent treatment with 5-FC significantly prolonged survival compared with that in animals with RG2 transduced tumors treated with PBS."1.33Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. ( Chen, TC; Kasahara, N; Kershaw, AD; Klatzmann, D; Solly, SK; Tai, CK; Wang, W, 2006)
"Rats bearing 9 L brain tumors were treated with an intratumoral injection of AdexCACD followed by intraperitoneal administration of 5-FC."1.31In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. ( Adachi, Y; Furuta, T; Hamada, H; Ichikawa, T; Matsumoto, K; Ohmoto, T; Ono, Y; Tamiya, T; Yoshida, Y, 2000)
" New interim measures of therapeutic response would be particularly useful in the development of cancer chemosensitization gene therapy by facilitating optimization of gene transfer protocols and prodrug dosing schedules."1.31Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. ( Chenevert, TL; Hamstra, DA; Jonas, SJ; Rehemtulla, A; Rice, DJ; Ross, BD; Stegman, LD; Stout, KL, 2000)
" In vitro studies showed that 5-FC combined with CDase induced significant growth-inhibitory effects on the cultured glioma cells."1.27Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. ( Ito, T; Katsuragi, T; Kawamoto, K; Kawamura, Y; Matsumura, H; Nishiyama, T; Ohyama, A; Sakai, T; Yamamoto, N, 1985)

Research

Studies (46)

TimeframeStudies, this research(%)All Research%
pre-19902 (4.35)18.7374
1990's4 (8.70)18.2507
2000's17 (36.96)29.6817
2010's20 (43.48)24.3611
2020's3 (6.52)2.80

Authors

AuthorsStudies
Chen, SH1
Sun, JM1
Chen, BM1
Lin, SC1
Chang, HF1
Collins, S1
Chang, D1
Wu, SF1
Lu, YC1
Wang, W2
Chen, TC3
Kasahara, N9
Wang, HE1
Tai, CK3
Accomando, WP1
Rao, AR2
Hogan, DJ4
Newman, AM1
Nakao, A1
Alizadeh, AA1
Diehn, M1
Diago, OR4
Gammon, D4
Haghighi, A2
Gruber, HE8
Jolly, DJ8
Ostertag, D7
Cloughesy, TF3
Petrecca, K1
Walbert, T3
Butowski, N1
Salacz, M1
Perry, J1
Damek, D1
Bota, D1
Bettegowda, C1
Zhu, JJ2
Iwamoto, F1
Placantonakis, D1
Kim, L1
Elder, B1
Kaptain, G1
Cachia, D1
Moshel, Y1
Brem, S1
Piccioni, D3
Landolfi, J3
Chen, CC3
Gruber, H1
Hogan, D1
Accomando, W2
Montellano, TT1
Kheoh, T2
Kabbinavar, F1
Vogelbaum, MA3
Mitchell, LA1
Lopez Espinoza, F2
Mendoza, D1
Kato, Y1
Inagaki, A1
Hiraoka, K1
Robbins, JM5
Elder, JB2
Bloomfield, S2
Carter, B2
Kalkanis, SN2
Kesari, S2
Lai, A2
Lee, IY2
Liau, LM2
Mikkelsen, T2
Nghiemphu, P1
Das, A3
Lu, G1
Carvalho, LA1
Teng, J1
Fleming, RL1
Tabet, EI1
Zinter, M1
de Melo Reis, RA1
Tannous, BA1
Sun, CH2
Berg, K2
Hirschberg, H2
Philbrick, BD1
Adamson, DC1
Aboody, KS1
Najbauer, J1
Metz, MZ1
D'Apuzzo, M1
Gutova, M1
Annala, AJ1
Synold, TW1
Couture, LA1
Blanchard, S1
Moats, RA1
Garcia, E1
Aramburo, S1
Valenzuela, VV1
Frank, RT1
Barish, ME1
Brown, CE1
Kim, SU4
Badie, B1
Portnow, J1
Yin, D1
Zhai, Y1
Ibanez, CE3
Kells, AP1
Forsayeth, J1
Bankiewicz, KS1
Parry, PV1
Engh, JA1
Wang, F1
Zamora, G1
Trinidad, A1
Chun, C1
Kwon, YJ1
Madsen, SJ1
Huang, TT1
Parab, S1
Burnett, R2
Diago, O1
Hofman, FM1
Espinoza, FL1
Martin, B2
Pertschuk, D1
Ropper, AE1
Zeng, X1
Haragopal, H1
Anderson, JE1
Aljuboori, Z1
Han, I1
Abd-El-Barr, M1
Lee, HJ1
Sidman, RL1
Snyder, EY1
Viapiano, MS1
Chi, JH1
Teng, YD1
Nghiemphu, PL1
Chu, A1
Hanna, M1
McCarthy, D1
Mitchell, L1
Rodriguez-Aguirre, M1
Chung, T1
Na, J1
Kim, YI2
Chang, DY1
Kim, H1
Moon, HE1
Kang, KW1
Lee, DS1
Chung, JK1
Kim, SS1
Suh-Kim, H1
Paek, SH1
Youn, H1
Strebe, JK1
Lubin, JA1
Kuo, JS1
Lv, SQ2
Zhang, KB1
Zhang, EE1
Gao, FY1
Yin, CL1
Huang, CJ1
He, JQ2
Yang, H3
Shi, DZ1
Hu, WX1
Li, LX1
Chen, G1
Wei, D1
Gu, PY1
Ito, S2
Natsume, A2
Shimato, S2
Ohno, M1
Kato, T1
Chansakul, P1
Wakabayashi, T2
Johnson, AJ1
Ardiani, A1
Sanchez-Bonilla, M1
Black, ME2
Amundson, KK1
Buckley, T1
Galvão da Silva, AP1
Lin, AH1
Valenta, DT1
Perez, OD1
Chen, CI1
Pettersson, PL1
Daublebsky, V1
Hlavaty, J1
Gunzburg, W1
Fei, S1
Qi, X1
Kedong, S1
Guangchun, J1
Jian, L1
Wei, Q1
Kosaka, H1
Ichikawa, T3
Kurozumi, K2
Kambara, H2
Inoue, S1
Maruo, T1
Nakamura, K1
Hamada, H3
Date, I1
Barresi, V1
Belluardo, N1
Sipione, S1
Mudò, G1
Cattaneo, E1
Condorelli, DF1
Wang, B1
Yoshimura, I1
Liu, YS2
Tamiya, T2
Ono, Y2
Otsuka, S1
Adachi, Y2
Ohmoto, T2
Fischer, U1
Steffens, S1
Frank, S1
Rainov, NG1
Schulze-Osthoff, K1
Kramm, CM1
Conrad, C1
Miller, CR1
Ji, Y1
Gomez-Manzano, C1
Bharara, S1
McMurray, JS1
Lang, FF1
Wong, F1
Sawaya, R1
Yung, WK1
Fueyo, J1
Lü, SQ1
Wang, WJ1
Kershaw, AD1
Solly, SK1
Klatzmann, D1
Kaliberov, SA1
Market, JM1
Gillespie, GY1
Krendelchtchikova, V1
Della Manna, D1
Sellers, JC1
Kaliberova, LN1
Buchsbaum, DJ1
Takeuchi, H1
Fujii, M1
Ito, M1
Park, IH1
Bang, JH1
Yoshida, J1
Choi, JD1
Powers, CJ1
Vredenburgh, JJ1
Friedman, AH1
Sampson, JH1
Nishiyama, T2
Kawamura, Y2
Kawamoto, K2
Matsumura, H2
Yamamoto, N2
Ito, T2
Ohyama, A2
Katsuragi, T2
Sakai, T2
Ge, K2
Xu, L1
Zheng, Z1
Xu, D1
Sun, L1
Liu, X1
Wang, ZH2
Samuels, S1
Gama Sosa, MA1
Kolodny, EH2
Xu, LF1
Zheng, ZC1
Sun, LY1
Liu, XY1
Zagzag, D1
Zeng, B1
Matsumoto, K1
Furuta, T1
Yoshida, Y1
Stegman, LD1
Rehemtulla, A1
Hamstra, DA1
Rice, DJ1
Jonas, SJ1
Stout, KL1
Chenevert, TL1
Ross, BD1
Chang, JW1
Lee, H1
Kim, E1
Lee, Y1
Chung, SS1
Kim, JH1
Moriuchi, S1
Wolfe, D1
Tamura, M1
Yoshimine, T1
Miura, F1
Cohen, JB1
Glorioso, JC1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165]Phase 2/Phase 3403 participants (Actual)Interventional2015-11-30Terminated (stopped due to Sponsor Decision)
Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade Astrocytomas[NCT05686798]Phase 118 participants (Anticipated)Interventional2022-11-29Recruiting
A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC[NCT01470794]Phase 158 participants (Actual)Interventional2012-02-29Completed
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma[NCT01156584]Phase 154 participants (Actual)Interventional2010-07-31Completed
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extende[NCT01985256]Phase 117 participants (Actual)Interventional2014-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for flucytosine and Glioma

ArticleYear
Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
    Expert opinion on investigational drugs, 2019, Volume: 28, Issue:3

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cytosi

2019

Trials

5 trials available for flucytosine and Glioma

ArticleYear
Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 12-01, Volume: 26, Issue:23

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cyt

2020
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
    JAMA oncology, 2020, 12-01, Volume: 6, Issue:12

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop

2020
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
    Neuro-oncology, 2018, 09-03, Volume: 20, Issue:10

    Topics: Antimetabolites; Brain Neoplasms; Combined Modality Therapy; Cytosine Deaminase; Drug Synergism; Flu

2018
Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 10-01, Volume: 24, Issue:19

    Topics: Aged; Animals; Autopsy; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flucyt

2018
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
    Science translational medicine, 2016, 06-01, Volume: 8, Issue:341

    Topics: Confidence Intervals; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Vectors; Glioma; Prodru

2016

Other Studies

40 other studies available for flucytosine and Glioma

ArticleYear
Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
    International journal of molecular sciences, 2020, Feb-20, Volume: 21, Issue:4

    Topics: Animals; Aziridines; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Escherichia coli Protein

2020
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
    Neuro-oncology, 2017, Jul-01, Volume: 19, Issue:7

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Disease Model

2017
Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.
    Journal of the National Cancer Institute, 2019, 03-01, Volume: 111, Issue:3

    Topics: Administration, Intranasal; Animals; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic

2019
Photochemical Internalization Enhanced Nonviral Suicide Gene Therapy.
    Methods in molecular biology (Clifton, N.J.), 2019, Volume: 1895

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorou

2019
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
    Science translational medicine, 2013, May-08, Volume: 5, Issue:184

    Topics: Animals; Cell Line; Cytosine Deaminase; Female; Flow Cytometry; Flucytosine; Fluorouracil; Glioma; H

2013
Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model.
    Cancer gene therapy, 2013, Volume: 20, Issue:6

    Topics: Animals; Brain Neoplasms; Convection; Cytosine Deaminase; Drug Delivery Systems; Flucytosine; Geneti

2013
Neural stem cell-mediated enzyme/prodrug therapy for glioma.
    Neurosurgery, 2013, Volume: 73, Issue:2

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Glioma; Humans; Mi

2013
Increased sensitivity of glioma cells to 5-fluorocytosine following photo-chemical internalization enhanced nonviral transfection of the cytosine deaminase suicide gene.
    Journal of neuro-oncology, 2014, Volume: 118, Issue:1

    Topics: Antifungal Agents; Cell Line, Tumor; Cytosine Deaminase; Dose-Response Relationship, Drug; Flucytosi

2014
Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
    Human gene therapy, 2015, Volume: 26, Issue:2

    Topics: Animals; Antibodies, Neutralizing; Antimetabolites; Brain Neoplasms; Clinical Trials as Topic; Cytos

2015
Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells.
    Neurosurgery, 2016, Volume: 79, Issue:3

    Topics: Animals; Cytosine Deaminase; Flucytosine; Fluorouracil; Ganciclovir; Genetic Engineering; Genetic Th

2016
Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas.
    Theranostics, 2016, Volume: 6, Issue:10

    Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cytosine Deaminase; Dihydrouracil Dehy

2016
"Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma.
    Neurosurgery, 2016, Volume: 79, Issue:6

    Topics: Brain Neoplasms; Flucytosine; Glioblastoma; Glioma; Humans

2016
Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study.
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:1

    Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytosine Deaminase; DNA Primers; Es

2009
Pharmacokinetics and the bystander effect in CD::UPRT/5-FC bi-gene therapy of glioma.
    Chinese medical journal, 2009, Jun-05, Volume: 122, Issue:11

    Topics: Animals; Antimetabolites; Cell Line; Cytosine Deaminase; Flucytosine; Genetic Therapy; Glioma; Human

2009
Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma.
    Cancer gene therapy, 2010, Volume: 17, Issue:5

    Topics: Animals; Bystander Effect; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flu

2010
Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications.
    Cancer gene therapy, 2011, Volume: 18, Issue:8

    Topics: Animals; Artificial Gene Fusion; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Flucy

2011
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl

2012
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl

2012
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl

2012
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl

2012
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl

2012
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl

2012
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl

2012
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl

2012
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl

2012
The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:2

    Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Genetic Ther

2012
Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma.
    Cancer gene therapy, 2012, Volume: 19, Issue:8

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coculture Techniques; Cytosine Deaminase;

2012
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
    Cancer gene therapy, 2003, Volume: 10, Issue:5

    Topics: Animals; Brain Neoplasms; Cells, Cultured; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluoro

2003
Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro.
    Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica, 2003, Volume: 35, Issue:5

    Topics: Cell Death; Cell Division; Culture Media; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic The

2003
Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus.
    Journal of neuro-oncology, 2004, Volume: 66, Issue:1-2

    Topics: Adenoviridae; Antimetabolites; Apoptosis; Caspase 3; Caspase 9; Caspase Inhibitors; Caspases; Cytoch

2004
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.
    Oncogene, 2005, Feb-10, Volume: 24, Issue:7

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Ganciclovir; Genes, Transgeni

2005
Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
    Cancer gene therapy, 2005, Volume: 12, Issue:3

    Topics: Adenoviridae; Adenovirus E1A Proteins; Base Sequence; Blotting, Western; Cell Line, Tumor; Chromatog

2005
[Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2004, Volume: 29, Issue:2

    Topics: Brain Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Th

2004
Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2005, Volume: 12, Issue:5

    Topics: Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Flucytosine; Genes, Transgenic, Suicide

2005
Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.
    Neurosurgical focus, 2006, Apr-15, Volume: 20, Issue:4

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA, Viral; Encep

2006
Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.
    Gene therapy, 2007, Volume: 14, Issue:14

    Topics: Adenoviridae; Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy

2007
Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma.
    Gene therapy, 2007, Volume: 14, Issue:15

    Topics: Animals; Antimetabolites; Bystander Effect; Cell Line; Cell Line, Tumor; Cell Movement; Cisterna Mag

2007
Cryptococcal meningitis in patients with glioma: a report of two cases.
    Journal of neuro-oncology, 2008, Volume: 89, Issue:1

    Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk

2008
[Antineoplastic effect of 5-fluorocytosine and cytosine deaminase on brain tumor (author's transl)].
    Neurologia medico-chirurgica, 1982, Volume: 22, Issue:5

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine; Cytosine Deaminase; Drug Therapy, Combina

1982
Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine.
    International journal of cancer, 1997, May-16, Volume: 71, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Drug Resistance, Neop

1997
5-Fluorocytosine-mediated apoptosis and DNA damage in glioma cells engineered to express cytosine deaminase and their enhancement with interferon.
    Journal of neuro-oncology, 1998, Volume: 36, Issue:3

    Topics: 3T3 Cells; Animals; Apoptosis; Cytosine Deaminase; DNA; DNA Damage; Drug Synergism; Flucytosine; Gli

1998
[Experimental treatment of brain tumor cells using CD suicide gene].
    Shi yan sheng wu xue bao, 1996, Volume: 29, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Escherichia coli; Flu

1996
In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha.
    Journal of neuropathology and experimental neurology, 1999, Volume: 58, Issue:8

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Cell Survival; Cyto

1999
In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus.
    Cancer gene therapy, 2000, Volume: 7, Issue:1

    Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Brain; Brain Neoplasms; Cytosine Deaminase;

2000
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.
    Gene therapy, 2000, Volume: 7, Issue:12

    Topics: Animals; Antifungal Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Genetic Therapy; Gliom

2000
Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.
    Neurosurgery, 2000, Volume: 47, Issue:4

    Topics: Adenoviridae; Animals; Antimetabolites; Antiviral Agents; Artificial Gene Fusion; Brain Neoplasms; C

2000
Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model.
    Gene therapy, 2002, Volume: 9, Issue:9

    Topics: Animals; Antiviral Agents; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Ganciclovir; G

2002
Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.
    Cancer research, 1985, Volume: 45, Issue:4

    Topics: Animals; Brain Neoplasms; Capsules; Cytosine; Cytosine Deaminase; Drug Evaluation, Preclinical; Drug

1985